Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 17/20 | 0.86 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.54 |
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Herbimycin SCHEMBL25344099 | 1.00 | HSP90AA1 (0.86) | HSP90AA1ALDH1A1ERBB2HSP90AB1PDGFRA | |
| Herbimycin SCHEMBL29420374 | 1.00 | HSP90AA1 (0.86) | HSP90AA1ALDH1A1ERBB2HSP90AB1PDGFRA | |
| Herbimycin SCHEMBL21578242 | 1.00 | HSP90AA1 (0.86) | HSP90AA1ALDH1A1ERBB2HSP90AB1PDGFRA | |
| Herbimycin SCHEMBL13225932 | 1.00 | HSP90AA1 (0.86) | HSP90AA1ALDH1A1ERBB2HSP90AB1PDGFRA | |
| SCHEMBL13959587 | 0.98 | HSP90AA1 (0.82) | HSP90AA1ALDH1A1ERBB2HSP90AB1PDGFRA | |
| Macbecin SCHEMBL443301 | 0.95 | HSP90AA1 (0.77) | HSP90AA1ALDH1A1ERBB2HSP90AB1PDGFRA | |
| Macbecin SCHEMBL2682394 | 0.95 | HSP90AA1 (0.77) | HSP90AA1ALDH1A1ERBB2HSP90AB1PDGFRA | |
| Macbecin SCHEMBL13040899 | 0.95 | HSP90AA1 (0.77) | HSP90AA1ALDH1A1ERBB2HSP90AB1PDGFRA | |
| Macbecin SCHEMBL2682389 | 0.95 | HSP90AA1 (0.77) | HSP90AA1ALDH1A1ERBB2HSP90AB1PDGFRA | |
| Macbecin SCHEMBL12800037 | 0.95 | HSP90AA1 (0.77) | HSP90AA1ALDH1A1ERBB2HSP90AB1PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 13668 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| EP-4727558-A1 | NOVEL METHOD EMPLOYING ANTIBIOTICS WITH ACCRETION TO APATITE COATED IMPLANTS PREVENTING BACTERIAL ATTACHMENT AND INFECTION | Moroxite I AB (SE) | 2026-04-22 | — | — | EP | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIV OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2026-02-26 | — | — | US | claimed |
| US-20260027140-A1 | COMPOSITIONS AND METHODS FOR TREATING AND AMELIORATING RESPIRATORY CONDITIONS AND INFLAMMATION OF MUCOSA | ATOPIC MEDICAL INC (US) | 2026-01-29 | — | — | US | claimed |
| EP-4684811-A1 | NOVEL TREATMENT REGIMEN AND METHODS IN BONE HEALING | Moroxite AB (SE) | 2026-01-28 | — | — | EP | claimed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| EP-4673458-A1 | METHODS OF ENHANCING PRODUCTION OF METABOLITES IN BACTERIA | JOHN INNES CENTRE (GB) | 2026-01-07 | — | — | EP | claimed |
| US-20250360129-A1 | COMPOSITIONS AND METHODS OF USING TYROSINE KINASE INHIBITORS | UNIV YALE (US) | 2025-11-27 | — | — | US | claimed |
| WO-1995020960-A2 | DNA DAMAGING AGENTS IN COMBINATION WITH TYROSINE KINASE INHIBITORS | ARCH DEVELOPMENT CORPORATION (US) | 1995-08-10 | — | — | WO | claimed |
| EP-0664702-A1 | TUMORICIDAL ACTIVITY OF BENZOQUINONOID ANSAMYCINS AGAINST PROSTATE CANCER AND PRIMITIVE NEURAL MALIGNANCIES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-08-02 | — | — | EP | claimed |
| EP-0637963-A1 | CD28 PATHWAY IMMUNOREGULATION | The Regents of The University of Michigan (US) | 1995-02-15 | — | — | EP | claimed |
| WO-1994008578-A2 | TUMORICIDAL ACTIVITY OF BENZOQUINONOID ANSAMYCINS AGAINST PROSTATE CANCER AND PRIMITIVE NEURAL MALIGNANCIES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1994-04-28 | — | — | WO | claimed |
| EP-0393575-B1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | SEARLE & CO (US) | 1994-03-16 | — | — | EP | claimed |
| WO-1993019767-A1 | CD28 PATHWAY IMMUNOREGULATION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1993-10-14 | — | — | WO | claimed |
| US-5242397-A | Catheter device and method of use for intramural delivery of protein kinase C and tyrosine protein kinase inhibitors to prevent restenosis after balloon angioplasty | CEDARS-SINAI MEDICAL CENTER (US) | 1993-09-07 | — | — | US | claimed |
| EP-0541716-A1 | NOVEL METHODS AND COMPOSITIONS FOR TREATMENT OF ANGIOGENIC DISEASES | REPLIGEN CORPORATION (US) | 1993-05-19 | — | — | EP | claimed |
| WO-1992002240-A2 | NOVEL METHODS AND COMPOSITIONS FOR TREATMENT OF ANGIOGENIC DISEASES | REPLIGEN CORPORATION (US) | 1992-02-20 | — | — | WO | claimed |
| EP-0393575-A1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | G.D. Searle & Co. (US) | 1990-10-24 | — | — | EP | claimed |